PharmaEssentia (6446) is a TW-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of NT$486.8B, trading at NT
180.00 on the TAI. This SniperIQ fundamentals page covers PharmaEssentia's valuation (P/E 73.7x, P/B 12.7x), profitability (net margin 33.9%), revenue (NT
5.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapNT$486.8B
P/E (TTM)73.7x
Net Margin33.9%
Revenue (FY25)NT
5.6B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is PharmaEssentia's market cap?
PharmaEssentia (6446) has a market capitalization of approximately NT$486.8B, trading at NT
180.00 on the TAI. Market cap moves with the live share price.
What is PharmaEssentia's P/E ratio?
PharmaEssentia's trailing twelve-month P/E ratio is 73.7x, with a price-to-book (P/B) of 12.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PharmaEssentia?
PharmaEssentia runs a net profit margin of 33.9%, a gross margin of 88.1%, and an operating margin of 33.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PharmaEssentia generate?
PharmaEssentia reported revenue of NT
5.6B for fiscal year 2025, with net income of NT$5.0B and earnings per share (EPS) of 13.64. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PharmaEssentia pay a dividend?
PharmaEssentia offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is PharmaEssentia financially healthy?
PharmaEssentia carries a debt-to-equity ratio of 0.03x and a current ratio of 6.53x, with a market beta of 0.56. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PharmaEssentia a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PharmaEssentia (6446) the key facts are: market cap NT$486.8B, P/E 73.7x, revenue NT
5.6B, 52-week range 397.23804-1415.3352. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PharmaEssentia's full fundamentals live
Get PharmaEssentia's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.